Relapsed and refractory aggressive NHL: Time for a change

Shane Gangatharan, John Kuruvilla

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)


Despite improvements in treatment for aggressive non-Hodgkin lymphoma (NHL), the outcomes for patients with relapsed or refractory B- or T-cell NHL after primary therapy remain poor. While some patients may be cured by the standard of care of salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), this treatment is unsuitable for the majority. Advances in disease biology and novel therapies have created uncertainty as to the role of old standards and opportunities to develop new rationally developed treatment options. We will review the standard approaches in this disease area and highlight areas that merit further study.

Original languageEnglish
Pages (from-to)72-79
Number of pages8
JournalTransfusion and Apheresis Science
Issue number1
Publication statusPublished - Aug 2013
Externally publishedYes


Dive into the research topics of 'Relapsed and refractory aggressive NHL: Time for a change'. Together they form a unique fingerprint.

Cite this